symbol,final_url,canonical_url,domain,author_name,publisher_name,date_published,published_at,headline,source,url,title,summary,full_text,word_count,language,relevance_score
AZN.L,https://www.thehindubusinessline.com/companies/trump-announces-astrazeneca-drug-price-cuts-for-tariff-reprieve/article70150897.ece,https://www.bloomberg.com/news/articles/2025-10-10/astrazeneca-is-said-to-reach-landmark-drug-price-deal-with-trump,www.thehindubusinessline.com,Bloomberg,BusinessLine,2025-10-11T04:12:52.000Z,2025-10-11T04:12:52Z,Trump announces AstraZeneca drug price cuts for tariff reprieve,thehindubusinessline.com,https://www.thehindubusinessline.com/companies/trump-announces-astrazeneca-drug-price-cuts-for-tariff-reprieve/article70150897.ece,Trump announces AstraZeneca drug price cuts for tariff reprieve - The Hindu BusinessLine,"Trump announces deal with AstraZeneca to lower drug prices for Americans in exchange for tariff relief, impacting healthcare costs.","+ 328.72 + 103.55 -221.00 + 992.00 + 261.00 + 328.72 + 103.55 + 103.55 -221.00 -221.00 + 992.00 Get businessline apps on Connect with us TO ENJOY ADDITIONAL BENEFITS Connect With Us Get BusinessLine apps on The deal is similar to a pact announced last week by Pfizer Inc | Photo Credit: Dado Ruvic US President Donald Trump has announced a deal with AstraZeneca Plc to slash consumer prices on some of the company‚Äôs drugs in exchange for tariff relief, in the second major deal between the White House and a pharmaceutical company seeking to reduce healthcare costs for Americans. ‚ÄúAstraZeneca, the largest pharmaceutical manufacturer in the UK, is committing to offer Americans major discounts on their vast catalogue of prescription drugs,‚Äù Trump said Friday in the Oval Office, where he was joined by AstraZeneca Chief Executive Officer Pascal Soriot. The deal ‚Äî similar to a pact announced last week by Pfizer Inc . ‚Äî will see AstraZeneca slash what it charges for its medicines in exchange for three years of relief from threatened tariffs on the pharmaceutical industry. The company will launch all of its new medicines in the US at the lowest prices offered to peer countries, as well as provide the company‚Äôs medicines to the Medicaid health insurance programme for low-income and disabled people at steeply discounted prices. ‚ÄúYou‚Äôre going to pay whatever the lowest price anywhere in the world is,‚Äù Trump said. The British drugmaker will expand the number of products sold through its direct-to-consumer website, AstraZeneca Direct at what Trump described as ‚Äúheavily reduced‚Äù cost, and make those medicines available on the TrumpRx website once it launches. The deal is the latest in what Trump administration officials say are a series of voluntary measures drugmakers are implementing to stave off more draconian moves by the government. Over the summer, Trump sent letters to 17 of the world‚Äôs biggest pharmaceutical companies with a list of demands. They included lower prices for the Medicaid insurance program for low-income and disabled people, direct sales of discounted drugs to patients and the introduction of newly approved medicines at the same prices in the US as in other developed countries. A pact with the British pharmaceutical powerhouse advances the Trump administration‚Äôs efforts and may lure other companies to the negotiating table. Soriot broke ranks with his peers in the industry in July, saying the US should pay similar prices for newly developed drugs as other wealthy countries. The financial implications of the deal remain unclear. The tariff threat for AstraZeneca is somewhat contained because it makes most of the medicine it sells in the US domestically. In September, Astra launched a new direct-to-consumer platform, where patients can get the diabetes drug Farxiga and the asthma inhaler Airsupra for as much as 70 per cent off their list prices. Drugs expected to see price cuts under the Trump deal include Airsupra, Farxiga, and COPD medicine Bevespi, according to a chart displayed at the event. Farxiga was Astra‚Äôs best-selling drug last year with $7.7 billion in sales, but prices were already set to come down as part of the Medicare drug price negotiation programme for 2026. Soriot was with Centers for Medicare & Medicaid Services Administrator Mehmet Oz on Thursday in Virginia, where the company is expanding its US manufacturing as part of its $50-billion investment in the US. ‚ÄúWe have more coming, but this is a very important one,‚Äù Oz said on Friday in the Oval Office, suggesting additional drug companies are likely to announce similar deals soon. Trump has called on drugmakers to make more of their medicines in the country, and the administration has launched an investigation into whether the lack of local production is a national security threat. Americans have traditionally paid the highest prices in the world for drugs. The structure positioned the US at the epicenter of a multibillion dollar market that generated scores of breakthrough medicines. It also allowed wealthy countries in Europe and elsewhere to draft off of American investment and reap the benefits without paying an equivalent share of the cost. The Trump administration has vowed to change the calculus through a concept known as most-favoured nation pricing. It would require companies to offer their drugs in the US at prices that are equivalent or lower than those in other countries. Investors initially feared that tariffs and rules around drug pricing would be a significant blow to the bottom line for pharmaceutical companies. As the deals have rolled out, Wall Street has interpreted drugmakers‚Äô commitments as having less of a financial impact than originally anticipated. More stories like this are available on bloomberg.com ¬©2025 Bloomberg L.P. Published on October 11, 2025 Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments. We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle. Terms & conditions | Institutional Subscriber",867,en,0.52
AZN.L,https://finance.yahoo.com/news/j-p-morgan-maintains-buy-023546127.html,https://finance.yahoo.com/news/j-p-morgan-maintains-buy-023546127.html,finance.yahoo.com,,Yahoo Finance,2025-10-23T02:35:46.000Z,2025-10-23T02:35:46Z,"J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a ¬£140 PT",finance.yahoo.com,https://finance.yahoo.com/news/j-p-morgan-maintains-buy-023546127.html,"J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a ¬£140 PT","AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to buy right now. AstraZeneca PLC (NASDAQ:AZN) received a rating update from J.P. Morgan analyst Richard Vosser on October 20, who assigned the stock a Buy rating with a ¬£140 price target. The rating update followed AstraZeneca PLC‚Äôs (NASDAQ:AZN) announcement of positive results [‚Ä¶]","AstraZeneca PLC (NASDAQ: AZN ) is one of the best long term low volatility stocks to buy right now . AstraZeneca PLC (NASDAQ:AZN) received a rating update from J.P. Morgan analyst Richard Vosser on October 20, who assigned the stock a Buy rating with a ¬£140 price target. The rating update followed AstraZeneca PLC‚Äôs (NASDAQ:AZN) announcement of positive results from the TROPION-Breast02 Phase III trial on October 19. The results showed that AstraZeneca and Daiichi Sankyo‚Äôs Datroway (datopotamab deruxtecan) exhibited a clinically meaningful and statistically significant improvement for ‚Äúthe dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator‚Äôs choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.‚Äù Management reported that Datroway is the first and only therapy to considerably improve the overall survival compared to chemotherapy in this patient population, showing a ‚Äúhighly statistically significant and clinically meaningful 43% reduction in patients‚Äô risk of disease progression or death‚Äù. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you‚Äôre looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now . Disclosure: None. This article is originally published at Insider Monkey .",284,en,0.46
AZN.L,https://www.zacks.com/research-daily/2771214/top-research-reports-for-astrazeneca-rtx-applied-materials?cid=CS-ZC-FT-research_daily-2771214,https://www.zacks.com/research-daily/2771214/top-research-reports-for-astrazeneca-rtx-applied-materials,www.zacks.com,Zacks Investment Research,Zacks Investment Research,,2025-10-20T20:28:00Z,"Top Research Reports for AstraZeneca, RTX & Applied Materials",zacks.com,https://www.zacks.com/research-daily/2771214/top-research-reports-for-astrazeneca-rtx-applied-materials?cid=CS-ZC-FT-research_daily-2771214,"Top Research Reports for AstraZeneca, RTX & Applied Materials - October 20, 2025 - Zacks.com","AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.","Mark Vickery Published on October 20, 2025 | AZN Quick Quote AZN LH Quick Quote LH RSG Quick Quote RSG AMAT Quick Quote AMAT EME Quick Quote EME PKE Quick Quote PKE NTWK Quick Quote NTWK RTX Quick Quote RTX Per the Zacks analyst, Republic Services' initiative to adopt electric vehicles (EVs) reduces its environmental impact by lowering fleet emissions. Low liquidity is concerning. Per the Zacks analyst, EMCOR is benefiting from robust public spending and sustained demand for network and communications projects. A solid balance sheet and rising RPOs add to the tailwinds. The Zacks Analyst is bullish on Labcorp's strong acquisition pipeline aligned with its financial strategy and supportive of organic growth. The company's steady financial health looks encouraging. Per the Zacks analyst, Light & Wonder is likely to benefit from improved gaming content backed by automation, standardization, AI tools and process development for higher efficiency and scalability. The Zacks analyst believes that Delek US Holdings' location near the Permian Basin and well-integrated refining system support its operations, but warns of risks tied to its heavy debt burden. Per the Zacks Analyst, Arrow Electronics' expanding product portfolio across the infrastructure software, next-generation hardware and hybrid cloud architectures spaces, is a key driver. Per the Zacks analyst, decent loan demand, relatively higher rates and prudent expense management will aid Hilltop Holdings. A solid balance sheet makes its capital distributions sustainable. The Zacks analyst expects growing medical costs and unpredictable utilization trends to pressure Molina Healthcare's MCR, reducing its ability to retain premiums after covering claims. Per the Zacks analyst, UFP Industries is hurting from ongoing softness in housing starts and competitive pricing across its key business units. Besides, high costs are pressuring its margins.",285,en,0.46
AZN.L,https://www.insidermonkey.com/blog/j-p-morgan-maintains-a-buy-rating-on-astrazeneca-plc-azn-sets-a-140-pt-1631686/,https://www.insidermonkey.com/blog/j-p-morgan-maintains-a-buy-rating-on-astrazeneca-plc-azn-sets-a-140-pt-1631686/,www.insidermonkey.com,@insidermonkey,Insider Monkey,,2025-10-23T02:35:46Z,"J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a ¬£140 PT",insidermonkey.com,https://www.insidermonkey.com/blog/j-p-morgan-maintains-a-buy-rating-on-astrazeneca-plc-azn-sets-a-140-pt-1631686/,"J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a ¬£140 PT - Insider Monkey",AstraZeneca PLC (NASDAQ:AZN) is one of the¬†best long term low volatility stocks to buy right now. AstraZeneca PLC (NASDAQ:AZN) received a rating update from J.P.,"AstraZeneca PLC (NASDAQ: AZN ) is one of the best long term low volatility stocks to buy right now . AstraZeneca PLC (NASDAQ:AZN) received a rating update from J.P. Morgan analyst Richard Vosser on October 20, who assigned the stock a Buy rating with a ¬£140 price target. The rating update followed AstraZeneca PLC‚Äôs (NASDAQ:AZN) announcement of positive results from the TROPION-Breast02 Phase III trial on October 19. The results showed that AstraZeneca and Daiichi Sankyo‚Äôs Datroway (datopotamab deruxtecan) exhibited a clinically meaningful and statistically significant improvement for ‚Äúthe dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator‚Äôs choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.‚Äù Management reported that Datroway is the first and only therapy to considerably improve the overall survival compared to chemotherapy in this patient population, showing a ‚Äúhighly statistically significant and clinically meaningful 43% reduction in patients‚Äô risk of disease progression or death‚Äù. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now . Disclosure: None. This article is originally published at Insider Monkey . NASDAQ:AZN Yahoo Finance AstraZeneca PLC (NASDAQ:AZN)",294,en,0.4
AZN.L,https://www.benzinga.com/news/health-care/25/10/48011733/2-under-the-radar-health-tech-stocks-with-surging-momentum-scores,https://www.benzinga.com/news/health-care/25/10/48011733/2-under-the-radar-health-tech-stocks-with-surging-momentum-scores,www.benzinga.com,Vishaal Sanjay,Benzinga,,2025-10-03T09:05:55Z,2 Under-The-Radar Health-Tech Stocks With Surging Momentum Scores - AstraZeneca (NASDAQ:AZN),benzinga.com,https://www.benzinga.com/news/health-care/25/10/48011733/2-under-the-radar-health-tech-stocks-with-surging-momentum-scores,2 Under-The-Radar Health-Tech Stocks With Surging Momentum Scores - AstraZeneca (NASDAQ:AZN) - Benzinga,Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.,"Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga‚Äôs Edge Stock Rankings , showing remarkable strength and fervor over the past week. In Benzinga‚Äôs Edge Rankings, the Momentum score basically indicates the strength of a stock relative to all other stocks ranked. It considers price movements and volatility across multiple time frames, before ranking them individually as a percentile against others. See Also: This Chinese Automaker Is Running Circles Around Tesla In 2025: Xpeng Stock Soars As EV Demand Heats Up In China Over the past week, these two health-tech stocks have seen significant improvements in their respective momentum scores, and here's why? Swiss medtech company, Sophia Genetics SA (NASDAQ: SOPH ), has seen its Benzinga Momentum score surge over the past week, rising from 32.45 to 81.80. This comes following the stock‚Äôs 30% surge over the past month, after the company expanded its collaboration with AstraZeneca PLC (NASDAQ: AZN ) to jointly develop an AI-powered next-generation sequencing solution targeting breast and prostate cancer. The stock scores high on Momentum in Benzinga‚Äôs Edge Stock Rankings , with a favorable price trend in the short, medium and long terms. Click here for deeper insights into the stock, its peers and competitors. New York-headquartered DarioHealth Corp. (NASDAQ: DRIO ) makes personalized health management solutions, particularly for those suffering from chronic conditions. The stock‚Äôs Momentum score surged from 7.69 to 59.45 within the span of a week, in line with the stock that has soared over 83% within the past month. This rally has been driven by the company‚Äôs announcement that it had formed a committee to explore a potential sale, merger or business combination. According to Benzinga‚Äôs Edge Stock Rankings , the stock does fairly well on Momentum, with a favorable price trend in the short, medium and long terms. Click here for deeper insights into the stock, its peers and competitors. Read More: Photo courtesy: Korot Yurii on Shutterstock.com ¬© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.",361,en,0.4
AZN.L,https://finance.yahoo.com/news/astrazeneca-stock-10-tariff-news-162246863.html,https://www.fool.com/investing/2025/10/02/astrazeneca-stock-is-up-10-on-tariff-news-but-is-t/,finance.yahoo.com,,Yahoo Finance,2025-10-02T16:22:46.000Z,2025-10-02T16:22:46Z,AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?,finance.yahoo.com,https://finance.yahoo.com/news/astrazeneca-stock-10-tariff-news-162246863.html,AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?,The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.,"AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. 10 stocks we like better than AstraZeneca Plc ‚Ä∫ Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early breast cancer. However, the main reason for AstraZeneca's big gain was Pfizer 's (NYSE: PFE) announcement of a deal with the Trump administration. Pfizer CEO Albert Bourla appeared with President Donald Trump at a press conference on Tuesday to announce the landmark agreement. Pfizer plans to slash the prices on many of its prescription drugs in the U.S. and invest $70 billion in expanding its domestic operations. It will also participate in a new TrumpRx website that will help consumers find medications at discounted prices. In return, Pfizer will enjoy a three-year grace period during which it won't be affected by the Trump administration's tariffs on pharmaceutical imports to the U.S. Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the way. As the fourth-largest pharmaceutical company based on market cap , AstraZeneca is likely to be among the drugmakers lining up to follow in Pfizer's footsteps. Second, like Pfizer, AstraZeneca already has plans to expand in the U.S. CEO Pascal Soriot said in the company's 2025 first-half update, ""As we enter our next phase of growth, we have pledged $50 billion to continue to grow in the U.S., which includes the largest manufacturing investment in AstraZeneca's history, set for Virginia."" The bottom line is that the chances seem to be pretty good that his company will be able to secure an exemption from tariffs over the next three years, as Pfizer has. Some of the uncertainty that was hovering over the entire biopharmaceutical industry, including AstraZeneca, has now been lifted. Is the stock a buy? Maybe so. For one thing, it is priced reasonably with a forward price-to-earnings ratio of around 15, and it continues to deliver strong earnings growth. The company is also making great strides with its pipeline, announcing more than a dozen positive results from late-stage clinical studies in recent months. I think AstraZeneca should be able to deliver solid gains for long-term investors. It's not the best pharma stock on the market, in my view, but it's still a pretty good one. Before you buy stock in AstraZeneca Plc, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now‚Ä¶ and AstraZeneca Plc wasn‚Äôt one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you‚Äôd have $631,456 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you‚Äôd have $1,147,755 !* Now, it‚Äôs worth noting Stock Advisor‚Äôs total average return is 1,064 % ‚Äî a market-crushing outperformance compared to 191% for the S&P 500. Don‚Äôt miss out on the latest top 10 list, available when you join Stock Advisor . See the 10 stocks ¬ª *Stock Advisor returns as of September 29, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy . AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy? was originally published by The Motley Fool",625,en,0.4
AZN.L,https://finance.yahoo.com/news/astrazeneca-azn-jumps-time-high-074855557.html,https://finance.yahoo.com/news/astrazeneca-azn-jumps-time-high-074855557.html,finance.yahoo.com,,Yahoo Finance,2025-10-02T07:48:55.000Z,2025-10-02T07:48:55Z,AstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff Delay,finance.yahoo.com,https://finance.yahoo.com/news/astrazeneca-azn-jumps-time-high-074855557.html,AstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff Delay,"We recently published 10 Stocks Stealing The Spotlight Today. AstraZeneca PLC (NASDAQ:AZN) is one of the top performers on Wednesday. AstraZeneca saw its share prices jump to a new all-time high on Wednesday, as investors cheered reports that President Donald Trump delayed the imposition of a 100-percent tariff on all pharmaceutical imports. A report by [‚Ä¶]","We recently published 10 Stocks Stealing The Spotlight Today . AstraZeneca PLC (NASDAQ:AZN) is one of the top performers on Wednesday. AstraZeneca saw its share prices jump to a new all-time high on Wednesday, as investors cheered reports that President Donald Trump delayed the imposition of a 100-percent tariff on all pharmaceutical imports. A report by Politico quoting a White House official said that Trump delayed the imposition of drug levies, set to take effect today, October 1, as the US government negotiates drug pricing with pharmaceutical giants. Following the news, AstraZeneca PLC (NASDAQ:AZN) soared to its highest 52-week price of $84.61 before trimming gains to end the day just up by 9.96 percent at $84.36 apiece. AstraZeneca PLC (NASDAQ:AZN) rallied alongside its counterparts in the US and Europe, helped by Pfizer Inc.‚Äôs landmark deal with the US government to lower drug prices for Americans and make them at par with prices in other key developing countries. Analysts said they expected drugmakers to follow suit in return for lower tariffs on their drugs entering the US. ‚ÄúWe expect EU pharma to follow suit and negotiate with the Trump administration for exemptions,‚Äù Lucy Coutts, investment director at wealth managers JM Finn, was quoted as saying in a report by Reuters. JPMorgan also said that it expects the Pfizer deal to become the bellwether for other drug companies in their negotiation strategies. While we acknowledge the potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now . Disclosure: None. This article is originally published at Insider Monkey .",325,en,0.4
AZN.L,https://www.cnbc.com/2025/10/01/cnbcs-uk-exchange-newsletter-astrazeneca-gets-a-shot-on-wall-street.html,https://www.cnbc.com/2025/10/01/cnbcs-uk-exchange-newsletter-astrazeneca-gets-a-shot-on-wall-street.html,www.cnbc.com,Ian King,CNBC,2025-10-01T05:30:01+0000,2025-10-01T05:30:01Z,CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street,cnbc.com,https://www.cnbc.com/2025/10/01/cnbcs-uk-exchange-newsletter-astrazeneca-gets-a-shot-on-wall-street.html,CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street,"The¬†British¬†government should not get complacent about AstraZeneca's U.S. listing, as it paves the way for a full one in New York.","This report is from this week's CNBC's UK Exchange newsletter. Like what you see? You can subscribe here. There is an old British saying about buses: you wait ages for one and then two arrive at once. Pharmaceuticals analysts experienced something similar on Monday as the big two U.K. drugmakers ‚Äî GSK and AstraZeneca ‚Äî delivered major announcements. GSK said Emma Walmsley, its CEO of nine years, who steered it through its demerger (its former consumer healthcare arm is now a separate company called Haleon), will leave at the end of the year. Her successor is Luke Miels, currently chief commercial officer, was poached from AZ amid acrimony eight years ago. AZ, meanwhile, announced plans to ""harmonise its share listing structure to deliver a global listing for global investors in a global company"". In practice, that means delisting its American Depositary Receipts (ADRs) from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange. ADRs are tradable certificates issued by U.S. banks representing a specific number of shares (usually one) of a foreign company. They tend to be less liquid than fully listed stocks ‚Äî and that deters some investors. The move was welcomed by investors, with shares up 0.8% on Monday. It should bring in new U.S. investors, especially if ‚Äî although this is not a given ‚Äî AZ eventually gains membership of the S&P 500. At first blush, it confirms fears first aired when, in July, The Times reported that CEO Pascal Soriot wanted to move AZ's stock market listing to the U.S. The British newspaper said Soriot, who today marks 13 years at the helm, had spoken privately of doing this on several occasions and had even discussed moving AZ's domicile. Soriot fanned the flames when, at subsequent results briefings, he did not deny the report and even called AZ a ""very American company."" AZ is among several big pharma companies to recently pause or postpone U.K. investments amid frustration at the country's drug-pricing regime. Accordingly, some interpret this as another blow to the London Stock Exchange (LSE), which is indeed how it was reported locally. A clutch of big names, all former FTSE 100 members, have moved their primary listing away from the U.K. lately. The defections began when, in 2021, BHP Group (previously BHP Billiton) ‚Äî at the time the FTSE's most valuable company ‚Äî announced plans to switch from a dual-listed structure, in which its shares were listed in both the U.K. and Australia, to a single primary listing on the Australian Securities Exchange (ASX). This was essentially a cost-saving and simplification exercise and few alarm bells rang at the time, not least because BHP retained a standard listing on the LSE, allowing British investors to remain exposed to the business. Moreover, BHP had no real assets in the U.K., other than a head office. The following year, the plumbing and heating products distributor Ferguson ‚Äî a U.K. stock market stalwart for decades under its former name of Wolseley ‚Äî moved its primary listing to New York. Again, this was no surprise, since North America by then accounted for more than 90% of its sales. There was still no panic when, in March 2023, CRH ‚Äî the world's biggest building materials supplier ‚Äî chose to switch to New York. After all, having only had a primary listing in London for 12 years, CRH was essentially an Irish company generating more than three-quarters of its earnings in the U.S. There was more disquiet when Flutter Entertainment, owner of successful betting and gaming businesses such as Paddy Power, Betfair, Sky Betting & Gaming and the U.S. business FanDuel, said it was considering moving its main listing to New York. It has since done so. This was altogether more serious as Flutter, the Irish-founded Paddy Power aside, was essentially British and a big player in its domestic market. Compounding concerns, later that year, the Cambridge-based chip designer Arm Holdings opted to list on Nasdaq instead of the LSE on its return to the stock market. Since then, the Anglo-German tour operator TUI has moved from a dual listing in London and Frankfurt to a single one in the latter, while the FTSE 100 plant and equipment hire company Ashtead ‚Äî named after the Surrey village where it was founded ‚Äî has announced plans to move its primary listing from London to New York. This again reflects the fact that 90% of its business is now in North America. The bad news, like the London drizzle, has kept on coming: Just Eat Takeaway said last December it would move from a dual listing in London and Amsterdam to a single one in the latter; the same location was chosen in February this year by Unilever for its demerged ice cream business. Fast-fashion giant Shein was recently reported to have chosen Hong Kong over London for its forthcoming Initial Public Offering, and Wise (formerly Transferwise), a fintech founded in London by two Estonian entrepreneurs and now valued at more than ¬£11 billion ($14.78 billion), received shareholder approval in July to move its primary listing from London to New York. AZ's decision, though, may not be as bad as it looks. It was at pains to stress its ""current status as a U.K. listed, headquartered and tax resident company"" would not change and that this was all about attracting a broader mix of global investors and better access to New York's larger pools of capital. Nor does this look to be a move in search of a higher stock rating: AZ's price-to-earnings ratio exceeds not only those of European peers like Novo Nordisk and Roche, but also several U.S. peers including Pfizer, Bristol-Myers Squibb and Merck. The British government should not get complacent, however. This move potentially eases a full switch of listing to New York should Soriot's frustrations at the U.K. finally boil over. Rachel Reeves, the country's chancellor, could prove she is alert to the risk posed to the London market by removing Stamp Duty Reserve Tax, the anachronistic levy of 0.5% applied on all share purchases. But ‚Äî as it raises ¬£3 billion annually for the Treasury ‚Äî I wouldn't bet on this. Louise Hellem, chief economist at the CBI, discusses the Chancellor's options ahead of the U.K. government's upcoming Budget at the Labour Party Conference in Liverpool. Ruth Curtice, chief executive of Resolution Foundation, discusses potential plans to increase personal taxes and the outlook for migration at the Labour Party Conference in Liverpool. Ian King joins Squawk Box Europe on location in Canary Wharf to discuss why the U.K. isn't good at helping startups to scale up, even though it's created more ""unicorns"" than any other country outside the U.S. and China. ‚Äî Holly Ellyatt UK at a 'fork in the road,' Prime Minister Keir Starmer warns. At the Labour Party's annual conference in Liverpool, Starmer said Tuesday that Britain is facing ""renewal or decline."" His comments come as the right-wing party Reform UK appears to be leading in the polls. Bank bosses in the UK are calling for policy stability. Finance Minister Rachel Reeves' Autumn Budget is scheduled for Nov. 26. Ahead of it, CEOs from Barclays, Citi and J.P. Morgan told CNBC that the banking sector, while seeing an upturn, needs great clarity from the government . Barclays CEO doubles down on the UK. That's despite the prospect of the government increasing taxes on the banking sector in its upcoming budget. C.S. Venkatakrishnan, the bank's chief, said the tax would ""stifle growth,"" but still called the U.K. the bank's ""home."" ‚Äî Yeo Boon Ping We have a modern industrial strategy, which is taking seven, eight sectors in the economy, and giving a 10-year plan for each of them. Businesses ... can see what the policy framework is going to be for a 10-year period. ‚Äî Peter Kyle, U.K. secretary of state of business and trade London-listed stocks have advanced over the past week, with the FTSE 100 up 1.38% from Sept. 23. It ended Tuesday at 9,350.43 points, with concerns surrounding a potential U.S. government shutdown weighing on investors' minds. The yield on 10-year gilts ticked higher from 4.695% a week ago to 4.701% on Tuesday afternoon, as U.K. borrowing came into sharp focus during Chancellor Rachel Reeves' speech at the Labour party conference in Liverpool. Meanwhile, sterling dropped 0.71% against the dollar over the last week, reaching $1.34. ‚Äî Katrina Bishop Oct. 1: Nationwide Housing Prices Oct. 6: U.K. new car sales data Oct. 7: Halifax House Price Index ‚Äî Holly Ellyatt",1426,en,0.4
AZN.L,https://www.livemint.com/companies/news/trump-strikes-deal-with-german-merck-on-tariffs-and-ivf-costs-11760646945530.html,https://www.livemint.com/companies/news/trump-strikes-deal-with-german-merck-on-tariffs-and-ivf-costs-11760646945530.html,www.livemint.com,@mint,mint,2025-10-17T02:05:45+05:30,2025-10-16T20:35:45Z,Trump Strikes Deal With German Merck on Tariffs and IVF Costs,livemint.com,https://www.livemint.com/companies/news/trump-strikes-deal-with-german-merck-on-tariffs-and-ivf-costs-11760646945530.html,Trump Strikes Deal With German Merck on Tariffs and IVF Costs | Company Business News,"President Donald Trump announced a deal with Germany‚Äôs Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs, a step toward fulfilling his campaign promise of making IVF less expensive and more widely available in the US.","President Donald Trump announced a deal with Germany‚Äôs Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs, a step toward fulfilling his campaign promise of making IVF less expensive and more widely available in the US. The administration will be issuing guidance to allow employers to offer fertility perks as excepted benefits, a category that includes supplemental health coverage like dental and vision. The guidance will allow employers to offer add-on coverage at a fixed cost for patients and employers. The White House previously issued an executive order directing the administration to produce by May policy recommendations aimed at lowering the cost of expensive fertility treatments. The report never came. Now, five months later, it‚Äôs addressing the technology that can cost upwards of $15,000 per procedure. The ‚Äúresult will be healthier pregnancies, healthier babies and many more beautiful American children,‚Äù Trump said at a press conference from the Oval Office on Thursday. Fertility was a frequent theme on the campaign trail for Trump, who once called himself the ‚Äúfather of IVF‚Äù at a town hall. But it‚Äôs a sticking point for some of his conservative base, particularly after the Alabama Supreme Court ruled in 2023 that frozen embryos could be considered children. Some fertility clinics suspended treatment until the Republican governor signed legislation protecting providers from liability. ‚ÄúEndorsing IVF from the White House podium should have some positive impact on awareness and adoption for IVF, even if there are no actual financial benefits being provided to employers to adopt those benefits,‚Äù wrote Michael Cherny, an analyst at Leerink Partners, in a note to investors. Trump has been taking steps to lower health care prices. He struck deals with Pfizer Inc. and AstraZeneca Plc to delay threatened tariffs on their medicines in exchange for charging the same in the US as they do abroad. The pharmaceutical companies also agreed to cut the prices they offer to the Medicaid health insurance program for low-income and disabled Americans. ¬©2025 Bloomberg L.P. This article was generated from an automated news agency feed without modifications to text. Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates. Log in to our website to save your bookmarks. It'll just take a moment.",395,en,0.32
AZN.L,https://stockmarketwatch.com/stock-market-news/u-s-stock-futures-soar-as-trade-tensions-ease-earnings-season-kicks-off/54456/,https://stockmarketwatch.com/stock-market-news/u-s-stock-futures-soar-as-trade-tensions-ease-earnings-season-kicks-off/54456/,stockmarketwatch.com,Ed Liston,Stock Market News,2025-10-13T09:07:56-04:00,2025-10-13T13:07:56Z,"U.S. Stock Futures Soar as Trade Tensions Ease, Earnings Season Kicks Off",thestockmarketwatch.com,https://stockmarketwatch.com/stock-market-news/u-s-stock-futures-soar-as-trade-tensions-ease-earnings-season-kicks-off/54456/,"U.S. Stock Futures Soar as Trade Tensions Ease, Earnings Season Kicks Off - Stock Market Watch","U.S. equity futures are showing a strong rebound this Monday, October 13, 2025, signaling a positive start to the week for the stock market. This premarket","üî¥ See All Market Updates Live ‚Üí U.S. equity futures are showing a strong rebound this Monday, October 13, 2025, signaling a positive start to the week for the stock market. This premarket surge comes after President Donald Trump adopted a more conciliatory tone regarding trade relations with China over the weekend, easing investor anxieties that had led to a significant market downturn on Friday. The optimistic sentiment is driving futures higher across the board, with particular strength seen in technology and chipmaker stocks. Premarket Trading and Futures Movements As of Monday morning, U.S. stock futures are rallying robustly. Dow Jones Industrial Average ( DJIA ) futures are up approximately 0.9% to 1.44%, while S&P 500 ( SPX ) futures have climbed between 1.2% and 1.43%. The technology-heavy Nasdaq 100 ( NDX ) futures are leading the charge, advancing significantly by 1.4% to 2.69%. This positive momentum follows a challenging end to last week, where renewed U.S.-China trade tensions triggered a sharp sell-off across major indexes. The SPDR S&P 500 ETF Trust ( SPY ) and Invesco QQQ Trust ETF ( QQQ ), which track the S&P 500 and Nasdaq 100 respectively, are also showing considerable gains in premarket trading. The shift in market sentiment is largely attributed to President Trump 's remarks, wherein he stated, ""Don't worry about China, it will all be fine,"" suggesting a de-escalation of trade rhetoric. This has provided a much-needed boost after Friday's session saw the S&P 500 experience its worst day since April, plummeting 2.7%, and the Nasdaq Composite ( IXIC ) recording its biggest single-day decline since April 10, falling 3.6%. The Dow Jones also slid 1.9% on Friday, contributing to weekly declines across all three major indexes. Current Performance of Major Market Indexes While Monday's trading is just beginning, the premarket activity suggests a strong recovery from Friday's losses. On Friday, October 10, the Dow Jones Industrial Average closed at 45,479.60, the S&P 500 at 6,552.51, and the Nasdaq Composite at 22,204.43. The broader U.S. stock market index (US500) has already seen gains, rising to 6638 points on October 13, a 1.30% increase from the previous session, and is up 13.27% over the past year. This performance indicates that despite recent volatility, the underlying market trend remains upward-biased over the longer term. The bond market is closed today in observance of Columbus Day, which is also recognized in some areas as Indigenous Peoples' Day. However, the 10-year Treasury bond yielded 4.03% and the two-year bond was at 3.50% at the end of last week. In commodities, crude oil futures are trading higher, hovering around $60.04 per barrel, while Gold Spot U.S. Dollar has risen 1.32% to approximately $4,071.30 per ounce, nearing its all-time record high. The U.S. Dollar Index spot is slightly higher at 99.1160. Upcoming Market Events The week ahead is packed with critical events that could significantly influence market direction. The ongoing U.S. government shutdown remains a key concern, as it threatens to delay the release of crucial economic data, including the Consumer Price Index (CPI), Producer Price Index (PPI), and retail sales figures. Despite the shutdown, some economic indicators are still expected. Investors will be watching for the NAHB Housing Market Index on Thursday, and Industrial Production, Building Permits, Housing Starts, Nonfarm Payrolls, and the Unemployment Rate on Friday. Earnings season officially kicks off this week, with major financial institutions set to report their third-quarter results. This will provide vital insights into corporate health and economic trends. Key earnings releases include: On the monetary policy front, markets are currently pricing in a 96.2% likelihood of the Federal Reserve cutting interest rates at its upcoming October meeting. Fed Chair Jerome Powell is also scheduled to speak on Tuesday, which could offer further clues on the central bank's outlook. Internationally, China's September trade figures, released today, showed exports surging 8.3% year-over-year and imports growing 7.4%, indicating resilience despite global trade tensions. Other international data to watch includes UK GDP and Eurozone Industrial Production. Major Stock News Today's premarket rally is broad-based, with several prominent companies making headlines. The ""Magnificent 7"" technology giants are seeing significant gains. Nvidia Corp. ( NVDA ) advanced 3.57%, Tesla Inc. ( TSLA ) was up 2.70%, Microsoft Corp. ( MSFT ) gained 1.51%, Apple Inc. ( AAPL ) rose by 1.75%, Amazon.com Inc. ( AMZN ) climbed 2.09%, Alphabet Inc. ( GOOGL ) (formerly Google) gained 1.52%, and Meta Platforms Inc. ( META ) saw a 1.56% increase. Notably, Amazon had been a major decliner on Friday, falling 5%. Chipmakers, which were hit hard by trade concerns last week, are poised for a strong rebound. Advanced Micro Devices ( AMD ), Nvidia ( NVDA ), and ON Semiconductor ( ON ) are all showing robust premarket gains. Fastenal Co. ( FAST ) jumped 2.57% ahead of its earnings release before the opening bell, with analysts expecting earnings of 30 cents per share on revenue of $2.13 billion. In other corporate news, shares of MP Materials ( MP ), a key player in rare earth minerals, surged 10% in premarket trading, while USA Rare Earth ( USAR ) also saw gains, benefiting from the easing of U.S.-China trade tensions after China had tightened rare-earth export controls. Cryptocurrency-related stocks, including Robinhood Markets ( HOOD ), MARA Holdings ( MARA ), Coinbase Global ( COIN ), and Riot Platforms ( RIOT ), are also on the rise as Bitcoin ( BTC ) rebounded over 3% to trade around $115,212.40 per coin. Conversely, Levi Strauss & Co. ( LEVI ) shares plunged 12.6% after the company warned that U.S. government tariffs would negatively impact its fourth-quarter margins. QUALCOMM Inc. ( QCOM ) also saw its shares drop 7.3% following news that China has initiated an antitrust investigation into its acquisition of Israel's Autotalks. Applied Digital Corp. ( APLD ) bucked the trend, with its shares jumping 16.1% after reporting better-than-expected first-quarter fiscal 2026 revenues of $64.22 million. AstraZeneca plc ( AZN ) shares saw a modest decline of 0.6% after reaching an agreement with the U.S. government to reduce drug prices. JPMorgan Chase ( JPM ) was up about 1% in premarket trading after announcing a $10 billion investment in sectors critical for national security. Overall, Monday, October 13, 2025, is shaping up to be a day of recovery and anticipation, with premarket gains driven by a softening in U.S.-China trade rhetoric and investors keenly awaiting the start of the Q3 earnings season. Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.",1104,en,0.2
AZN.L,https://stockmarketwatch.com/stock-market-news/stock-market-today-futures-surge-as-trade-tensions-ease-earnings-season-kicks-off/54450/,https://stockmarketwatch.com/stock-market-news/stock-market-today-futures-surge-as-trade-tensions-ease-earnings-season-kicks-off/54450/,stockmarketwatch.com,Ed Liston,Stock Market News,2025-10-13T06:07:58-04:00,2025-10-13T10:07:58Z,"Stock Market Today: Futures Surge as Trade Tensions Ease, Earnings Season Kicks Off",thestockmarketwatch.com,https://stockmarketwatch.com/stock-market-news/stock-market-today-futures-surge-as-trade-tensions-ease-earnings-season-kicks-off/54450/,"Stock Market Today: Futures Surge as Trade Tensions Ease, Earnings Season Kicks Off - Stock Market Watch","U.S. equity index futures are soaring this Monday, October 13, 2025, signaling a strong start to the trading week as investors breathe a collective sigh of","üöÄ Full Market Coverage Here ‚Üí U.S. equity index futures are soaring this Monday, October 13, 2025, signaling a strong start to the trading week as investors breathe a collective sigh of relief following a de-escalation in U.S.-China trade rhetoric. This morning's rally aims to recoup significant losses from Friday, which saw major indexes tumble amidst renewed tariff threats. The positive sentiment is also buoyed by expectations of further Federal Reserve rate cuts, even as an ongoing government shutdown continues to cast a shadow over economic data releases. Premarket trading indicates a robust rebound across the board. S&P 500 ( SPX ) futures are up approximately 1.2% to 1.5%, while Nasdaq 100 ( NDX ) futures are surging, gaining between 1.6% and 2.1%. Dow Jones Industrial Average ( DJIA ) futures are also showing strong upward momentum, climbing 0.7% to 1.12%. This significant premarket strength is largely attributed to President Donald Trump 's conciliatory remarks over the weekend, which eased fears of an escalating trade war with China after he had threatened 100% tariffs on Chinese imports on Friday. The ""Magnificent Seven"" tech giants are leading the charge in premarket trading. Nvidia ( NVDA ) is up 3.7%, Tesla ( TSLA ) has gained 2.8%, and Microsoft ( MSFT ) advanced 1.5%. Meta Platforms ( META ) and Alphabet ( GOOGL ) are also seeing gains, both rising 1.6%. In the commodities market, West Texas Intermediate (WTI) crude oil is trending higher, hovering near $59.76 per barrel, up around 1.4% to 1.6%. Gold prices are also rallying strongly, setting a new peak and rising around 0.8% to 1.3%, reflecting continued safe-haven demand alongside the improving risk sentiment. The U.S. 10-year Treasury yield, a key indicator for borrowing costs, is currently floating near 4.06%. The positive premarket activity follows a challenging end to last week. On Friday, October 10, 2025, U.S. stock markets experienced a significant sell-off, driven by heightened U.S.-China trade tensions and the lingering uncertainty from the ongoing federal government shutdown. The S&P 500 ( SPX ) tumbled 2.7% to close at 6,552.51, marking its most significant single-day drop since April. The tech-heavy Nasdaq Composite ( IXIC ) plummeted 3.6% to 22,204.43, also experiencing its largest single-day decline since April. The Dow Jones Industrial Average ( DJIA ) slid 1.9% to finish at 45,479.60. All three major indexes ended the week in negative territory. Amazon.com Inc. ( AMZN ) was a notable loser on Friday, with its stock price down 5%. This week is poised to be eventful, despite the continued U.S. government shutdown, which is now entering its third week. The shutdown is expected to delay the release of several key economic data points, including consumer price index (CPI), producer price index (PPI), retail sales, housing starts, and jobless claims. The CPI report, for instance, is now anticipated to be published on October 24. However, other scheduled updates, such as industrial production and various manufacturing surveys, are still expected. The Federal Reserve remains a key focus for investors. Markets are currently pricing in a nearly 96% chance of a 25-basis-point Fed rate cut in October, with an 87% possibility of another reduction in December. Several Fed officials are scheduled to speak throughout the week, with Philadelphia Fed President Anna Paulson addressing the public today. Their comments will be closely scrutinized for further clues on the central bank's monetary policy path. The third-quarter earnings season officially kicks off this week, with a deluge of reports from major financial institutions and other prominent companies. Investors will be closely watching these releases to gauge corporate health and the broader economic landscape. It's important to note that while U.S. stock markets ( NYSE and Nasdaq) are open today, October 13, for Columbus Day, the U.S. bond markets are closed. Beyond the broader market movements, several individual companies are making headlines. The easing of U.S.-China trade tensions is a significant development, especially after China's September exports surged 8.3% year-over-year, marking the fastest pace in six months. In corporate news, the burgeoning field of quantum computing is gaining significant attention, with major hyperscalers such as Microsoft ( MSFT ), Google ( GOOGL ), Amazon ( AMZN ), Oracle ( ORCL ), Meta Platforms ( META ), and Tesla ( TSLA ) actively integrating this technology into their infrastructure, positioning it as the ""next technological revolution"". Pharmaceutical giant AstraZeneca PLC ( AZN ) has reached a drug-pricing agreement with the Trump administration, mirroring a previous deal by Pfizer Inc. ( PFE ) to offer ""most-favored nation"" pricing. Johnson & Johnson ( JNJ ) is reportedly in discussions to acquire Protagonist Therapeutics Inc. ( PTGX ), with the two companies already collaborating on a treatment for ulcerative colitis. BASF SE ( BASFY ) announced it would sell a majority stake in its coatings unit to Carlyle Group Inc. ( CG ) for $6.7 billion, while retaining a 40% interest. MIPS, a GlobalFoundries ( GFS ) company, has appointed Moshe Hillel as its head of Business Development for Israel, aiming to accelerate the adoption of its RISC-V technology in the region. In the banking sector, Lloyds Banking Group PLC ( LYG ) has set aside an additional ¬£800 million to address potential compensation claims related to a motor finance scandal, bringing its total provision to nearly ¬£2 billion. On the international front, German farm machinery firm Krone has reportedly halted U.S. exports of large equipment due to ""hidden"" tariffs, highlighting ongoing trade complexities despite the recent easing of U.S.-China tensions. Indian IT services company HCL Technologies ( HCLTECH.NS ) is scheduled to announce its Q2 FY26 results today, with investors keen on management's commentary regarding its deal pipeline and demand outlook. Additionally, Reliance Power Ltd ( RPOWER.NS ) saw its Executive Director and CFO, Ashok Kumar Pal, resign with immediate effect following his arrest in connection with a financial probe. Suzlon Energy Ltd ( SUZLON.NS ) is also seeing some positive movement in its stock price, up 0.07% to ‚Çπ54.27. Fastenal Company ( FAST ) is expected to report its Q3 earnings today, with analysts anticipating 30 cents per share on $2.1 billion in sales. Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.",1048,en,0.2
